Healthcare, Pharma & Life Sciences

Ensera Launches Alliance Network to Streamline Combination Drug-Device Supply

Image
Ensera Launches Alliance Network to Streamline Combination Drug-Device Supply

Dublin – – October 01, 2026 -- Ensera, a global CDMO specializing in commercialization support for injectable drug programs, has launched the Ensera Alliance Network, uniting device platform and fill-finish specialists to streamline the commercialization of drug-device combination products.

Five specialist firms join the new coordination network

The network currently comprises injector platform providers SHL Medical, Stevanato Group and Ypsomed, alongside fill-finish specialists Argonaut Manufacturing Services and American Injectables. Ensera said it plans to expand the network over time by adding organizations whose capabilities and standards complement existing members.

Lundbeck's VYEPTI Hits 60% Improvement in Phase IV THRIVE Trial

Valby, Denmark – October 01, 2026 -- H. Lundbeck A/S reported that 60% of participants in its Phase IV THRIVE trial achieved 'much improved' or 'very much improved' status on a standardized patient scale after switching to eptinezumab, marketed as VYEPTI, following an inadequate response to a prior CGRP-targeting preventive migraine therapy.

Trial enrolled 164 adults who had failed one prior CGRP preventive treatment

The 24-week, open-label, multicenter trial (NCT06701526) was conducted in the United States and enrolled 164 adults with at least eight monthly migraine days who had previously used either a subcutaneous anti-CGRP monoclonal antibody or a preventive gepant, but had not received eptinezumab. Participants started on 100 mg of eptinezumab, escalating to 300 mg at week 12, with 147 receiving both infusions; 84% (138/164) completed the trial.

AlignRx Spotlights PBM Dominance Squeezing Community Pharmacies

Image
AlignRx Spotlights PBM Dominance Squeezing Community Pharmacies

Los Angeles – October 01, 2026 -- Three pharmacy benefit managers—CVS Caremark, Optum Rx, and Express Scripts—processed roughly 80% of U.S. prescription claims last year, a concentration that AlignRx says is squeezing independent pharmacies out of the market. The nation's largest independently owned Pharmacy Services Administrative Organization (PSAO) is the subject of a forthcoming feature on the public television series All Access with Andy Garcia, which examines the reimbursement pressures facing community pharmacies nationwide.

Vertically integrated PBMs leave pharmacies reimbursed below drug cost

The feature details how market consolidation among the three dominant PBMs has created a vertically integrated system in which patients face higher out-of-pocket costs and reduced choice. Community pharmacies, AlignRx says, are often reimbursed less than the cost of the medication they dispense, straining their ability to stay open.

Fresenius Takes Full Ownership of mAbxience in Biosimilars Push

Image
Fresenius Takes Full Ownership of mAbxience in Biosimilars Push

Madrid – October 01, 2026 -- Fresenius SE & Co. KGaA has completed the acquisition of the remaining 45% stake in mAbxience from Insud Pharma, giving the German healthcare group full ownership of the Spanish biosimilars manufacturer.

Fresenius consolidates control after four-year partnership

Fresenius first acquired a 55% majority stake in mAbxience in August 2022 and has consolidated the business since then. The deal closes out that ownership structure, placing mAbxience's biosimilars platform entirely within Fresenius Kabi's Biopharma division, which spans development, manufacturing and commercialization.

Emerald Clinical Trials Names Michael Stibilj CEO as CRO Scales APAC Platform

Image
Emerald Clinical Trials Names Michael Stibilj CEO as CRO Scales APAC Platform

Singapore – October 01, 2026 -- Emerald Clinical Trials has appointed Michael Stibilj as Chief Executive Officer, effective October 01, 2026, tasking the 30-year CRO veteran with leading the next phase of growth for a platform that now spans more than 1,000 professionals across 40-plus countries and 70-plus locations.

Stibilj joins from six years as Chief Operating Officer at Novotech

Before Novotech, Stibilj served three years as CEO of PPC Group and spent 22 years at IQVIA in regional and global leadership roles, with operational experience across China, Singapore and Australia.

Appointment follows the acquisition of Hongyi Clinical Development Services

The deal combined Emerald with Hongyi to create a clinical development platform supporting sponsors from first-in-human trials through post-marketing across China, Asia-Pacific, Europe and the Americas.

Lilly's Foundayo Cuts Cardiovascular Death Risk 53% in ACHIEVE-4 Trial

Image
Lilly's Foundayo Cuts Cardiovascular Death Risk 53% in ACHIEVE-4 Trial

Indianapolis – – October 01, 2026 -- Eli Lilly and Company (NYSE: LLY) reported that its oral GLP-1 therapy Foundayo (orforglipron) reduced cardiovascular death risk by 53% and all-cause death risk by 57% compared with insulin glargine in the Phase 3 ACHIEVE-4 trial, the largest and longest study of the medicine in type 2 diabetes to date.

Foundayo meets non-inferiority bar on major cardiovascular events

Among 2,749 participants randomized across 16 countries including the U.S., Germany, India, Brazil and South Korea, Foundayo showed a 16% lower risk of MACE-4 (cardiovascular death, heart attack, stroke or hospitalization for unstable angina) versus insulin glargine, with a hazard ratio of 0.84 (95.0% CI: 0.59 to 1.20), meeting the prespecified non-inferiority threshold. The risk of MACE-3 (cardiovascular death, heart attack or stroke) was 23% lower (hazard ratio: 0.77; 95.0% CI: 0.52 to 1.13).

Halozyme Names Ex-Incyte Commercial Chief Jim Daly to Board

Image
Halozyme Names Ex-Incyte Commercial Chief Jim Daly to Board

San Diego – October 01, 2026 -- Halozyme Therapeutics (Nasdaq: HALO) has appointed James "Jim" Daly to its Board of Directors, returning a veteran biopharmaceutical commercial executive to help steer the company's drug-delivery technology expansion.

Daly rejoins board after prior tenure, bringing three decades of launch experience

Daly previously served on Halozyme's board and has held senior commercial leadership roles at Incyte Corporation, Amgen and Glaxo Wellcome/GlaxoSmithKline. He was Executive Vice President and Chief Commercial Officer of Incyte from 2012 to 2015, following a decade at Amgen where he most recently served as Senior Vice President, North America Commercial Operations, Global Marketing and Commercial Development. Earlier, he spent more than 16 years at Glaxo Wellcome/GlaxoSmithKline, including as Senior Vice President and General Manager of the U.S. respiratory business.

Haemonetics to Report Fiscal Q2 2027 Results on Nov. 5

Image
Haemonetics to Report Fiscal Q2 2027 Results on Nov. 5

Boston – October 01, 2026 -- Haemonetics Corporation (NYSE: HAE) will publish its second quarter fiscal year 2027 financial results at 6:00 am ET on Thursday, October 01, 2026.

Haemonetics sets investor call for 8:00 am ET on November 5

The medical technology company will hold a conference call with investors and analysts two hours after the earnings release to discuss results and answer questions. Participants can access the call via teleconference after completing registration, which provides a dial-in number and personalized PIN.

Live webcast replay to remain available for one year

A live webcast of the call will be accessible on Haemonetics' investor relations website. The company will maintain a replay of the conference call and webcast for one year beginning October 01, 2026 at 11:00 am ET, using the same webcast link.

Midmark RTLS Adds Staff Duress Alerts to Epic Toolbox

Image
Midmark RTLS Adds Staff Duress Alerts to Epic Toolbox

Versailles, Ohio – October 01, 2026 -- Midmark RTLS has added its CareFlow RTLS Staff Duress solution to the Epic Toolbox in the Staff Duress category for 2026, integrating real-time, location-aware caregiver duress alerts directly into Epic's electronic health record system.

Badge-based alerts feed directly into Epic's push notification framework

CareFlow Staff Duress connects to Epic using HL7 FHIR-based APIs, allowing Midmark RTLS badges already worn by caregivers to trigger duress alerts with a discreet button press. When activated, Epic receives the staff member's identity and real-time location and notifies designated security and informational response groups through its push notification system. Responders can acknowledge or decline alerts within Epic itself, keeping emergency coordination inside existing clinical software.

Taejoon Ahn Named CEO of Washington Permanente Medical Group

Image
Taejoon Ahn Named CEO of Washington Permanente Medical Group

Seattle – October 01, 2026 -- Washington Permanente Medical Group (WPMG) has named Taejoon Ahn, MD, MPH, as its new CEO and executive medical director, placing him at the head of an organization that oversees more than 1,200 clinicians serving over 550,000 Kaiser Permanente members across Washington state.

Ahn succeeds interim leader Dorian Reid, who held the role since September 2025

Dr. Ahn takes over an independent, physician-owned medical group that works exclusively with Kaiser Permanente to deliver care in the region. The leadership transition closes a one-year interim period under Dorian Reid, MD.